We are leveraging our
knowledge of new autophagy
biology to create new therapeutics
Our Pipeline
Samsara is leveraging its knowledge of new autophagy biology to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat serious rare genetic diseases and neurodegenerative disorders with a strong genetic component. These diseases all have limited or no known treatment options.
We focus on identifying novel targets and mechanisms which have a strong genetic linkage to dysfunctional autophagy, and pair this new biology with the appropriate genetically driven disease where autophagy plays a driving role, and where we have generated strong in-house evidence of disease modification.
The Lysoseeker™ Platform
A unique approach for discovering new autophagy therapeutics.
Rare Monogenic Disease
What if we could offer real hope for serious rare genetic diseases?
Neurodegeneration
What if we could tackle the cause of Alzheimer’s and Parkinson’s Disease?
Our Pipeline
Samsara is leveraging its knowledge of new autophagy biology.
Neurodegeneration, lysosomal dysfunction and autophagy
There is a desperate need for novel therapies that can prevent the progressive neurodegeneration in debilitating diseases of ageing, such as Alzheimer’s, Parkinson’s and Huntington’s Disease.
New home and strengthening our scientific team
It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.
Autophagy, healthspan and lifespan
Our strategy in Samsara is to treat diseases where there is a high unmet need. But we also want to find out how our molecules work to affect healthspan and longevity.
Introducing Samsara
Over the last twenty years or so, the phenomenon of autophagy has become a hot topic in the world of biology.
© 2021 Samsara Therapeutics | Legal Information | Privacy
© 2021 Samsara Therapeutics
Legal Information | Privacy